iShares JPMorgan USD Emerging Markets Bond ETF vs Enveric Biosciences Inc — how do they compare? iShares JPMorgan USD Emerging Markets Bond ETF trades at $95.58, while Enveric Biosciences Inc trades at $1.37 (market cap $5.32M). The key difference: iShares JPMorgan USD Emerging Markets Bond ETF is trading nearer its 52-week high, Enveric Biosciences Inc nearer its low. Which is the better fit depends on your goals.
| EMB | ENVB | |
|---|---|---|
Sector | Fixed Income | Health |
52-Week High | $97.74 | $17.40 |
52-Week Low | $91.59 | $1.28 |
Market Cap | — | $5.32M |
Enterprise Value | — | $408.82K |
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
ENVB trades at $1.41, up 6.82% in the last session. The stock shows a bearish technical trend with moving averages signaling sell, but oscillators are neutral. Financially, the company reported a net loss of $8.77M for 2025, with negative ROE and ROA, though it consistently beat EPS expectations. Recent news highlights participation in investor conferences and progress with its neuroplastogen candidate EB-003.
Outlook is speculative with high risk due to negative profitability and cash burn, offset by strong analyst buy ratings (75%) and positive clinical updates. Key risks include funding needs and drug development hurdles, while catalysts hinge on regulatory milestones and partnership news.
Trailing returns across standard periods
EMB invests in U.S. dollar-denominated sovereign debt from emerging market countries. It provides exposure to government bonds from dozens of nations like Turkey, Mexico, and Brazil, offering a way to seek higher yields and geographic diversification.
Read more on EMB →Enveric Biosciences is a biotechnology company focused on developing next-generation psychedelic-inspired therapies for mental health and neuropsychiatric disorders.
Read more on ENVB →